Publication date: Jul 18, 2024
People from backgrounds that are economically/socially disadvantaged experienced disproportionately high COVID-19 death rates and had lower vaccination rates. Effective outreach strategies for increasing vaccine uptake during the pandemic are not fully known. Among patients receiving care at a Federally Qualified Health Center, we tested whether community engaged digitally-enabled outreach from a trusted clinician messenger increased COVID vaccine uptake. A 3-parallel-arm randomized controlled trial with a hybrid effectiveness-implementation design was conducted among patients ≥ 18 years old on study enrollment during 2021 with 1,650 assigned in 3:10:20 ratio; 2,328 were later selected for two subsequent implementation rounds. From April 13 to June 10, 2021, patients were proactively sent a text-messaging invitation to make an appointment for vaccination as part of the routine practice with a link to frequently asked questions (Arm 1, n = 150) with added personalized clinician recommendation alone (Arm 2, n = 500) or with enabled 2-way SMS messaging feature (Arm 3, n = 1,000). Further implementation used messaging addressing vaccine hesitancy (n = 1,323) or adverse reactions to vaccines (n = 1,005). The primary outcome was the completion of the first SARS-Cov-2 vaccine dose determined at 14, 30 and 90 days after outreach. Of 1,650 patients in effectiveness Arms, 61% was female. Vaccination rates for Arms 1, 2, and 3, were 6% (n = 9), 5. 4% (n = 27) and 3. 3% (n = 33) at 14 days, and 11. 5% (n = 17), 11. 6% (n = 58), and 8. 5% (n = 85) at 90 days, respectively, which were similar in pairwise comparisons. At 90 days, vaccination rates were similar across the two implementation rounds (3. 9% vs. 3. 6%) and were similar to the rate (3. 3%) among patients who were not selected for intervention arms or implementation rounds (n = 8,671). Digitally-enabled outreach that included SMS messaging outreach augmented with clinician recommendations did not improve COVID-19 vaccination rates. This study is registered at ClinicalTrails. gov Identifier: NC-T04952376.
Open Access PDF
Concepts | Keywords |
---|---|
Female | Adult |
June | Aged |
Pandemic | COVID-19 |
Vaccination | COVID-19 Vaccines |
COVID-19 Vaccines | |
Female | |
Humans | |
Male | |
Middle Aged | |
SARS-CoV-2 | |
Text Messaging | |
Vaccination | |
Vulnerable Populations |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | VO | vaccination |
disease | MESH | death |
disease | VO | effective |
disease | VO | vaccine |
disease | VO | effectiveness |
disease | VO | vaccine dose |
disease | IDO | intervention |
drug | DRUGBANK | Phencyclidine |
drug | DRUGBANK | Trestolone |
disease | VO | population |
disease | VO | protocol |
disease | VO | company |
drug | DRUGBANK | Etoperidone |
disease | VO | vaccinated |
disease | IDO | process |
disease | VO | device |
drug | DRUGBANK | Coenzyme M |
disease | VO | influenza vaccines |
disease | VO | Equity |
drug | DRUGBANK | Methylphenidate |
disease | VO | report |
disease | VO | publication |
disease | VO | USA |
disease | MESH | influenza |